Figure 1



Binding
Direct killing
C170
Colo205
HCT116
MFI
percentage dead cells
chimeric SC104
mouse SC104
human isotype
antibody concentration (µg/ml)

Figure 2



A
10000
1000
100
10
1
MFI
0.1
1
antibody concentration (µg/ml)
chimeric SC104
SEQ ID NO:7/
SEQ ID NO:9
human isotype
B
10000
1000
100
10
1
MFI
0.1
1
antibody concentration (µg/ml)
chimeric SC104
SEQ ID NO:8/
SEQ ID NO:10
human isotype

Figure 3



A
10000
1000
100
10
1
MFI
0.1
1
antibody concentration (µg/ml)
chimeric SC104
SEQ ID NO:7/
SEQ ID NO:11
human isotype
B
10000
1000
100
10
1
MFI
0.1
1
antibody concentration (µg/ml)
chimeric SC104
SEQ ID NO:8/
SEQ ID NO:12
human isotype

Figure 4



A
10000
1000
100
10
1
MFI
0.1
1
antibody concentration (µg/ml)
chimeric SC104
SEQ ID NO:16/ SEQ ID NO:15
SEQ ID NO:7/ SEQ ID NO:15
SEQ ID NO:7/ SEQ ID NO:9
SEQ ID NO:16/ SEQ ID NO:9
human isotype
B
10000
1000
100
10
1
MFI
0.1
1
antibody concentration (µg/ml)
chimeric SC104
SEQ ID NO:7/ SEQ ID NO:13
SEQ ID NO:7/ SEQ ID NO:11
SEQ ID NO:16/ SEQ ID NO:11
SEQ ID NO:16/ SEQ ID NO:13
human isotype

Figure 5



MFI
10000
1000
100
10
1
0.01
0.1
1
10
antibody concentration (µg/ml)
chimeric SC104
SEQ ID NO:7/ SEQ ID NO:19
SEQ ID NO:7/ SEQ ID NO:20
SEQ ID NO:7/ SEQ ID NO:21
SEQ ID NO:7/ SEQ ID NO:22
SEQ ID NO:7/ SEQ ID NO:23
SEQ ID NO:7/ SEQ ID NO:24
human isotype

Figure 6



A
10000
1000
100
10
1
MFI
0.1
1
10
antibody concentration (µg/ml)
chimeric SC104
SEQ ID NO:8/ SEQ ID NO:12
SEQ ID NO:8/ SEQ ID NO:10
SEQ ID NO:8/ SEQ ID NO:27
SEQ ID NO:8/ SEQ ID NO:26
human isotype
B
10000
1000
100
10
1
MFI
0.1
1
10
antibody concentration (µg/ml)
chimeric SC104
SEQ ID NO:7/ SEQ ID NO:11
SEQ ID NO:7/ SEQ ID NO:9
SEQ ID NO:7/ SEQ ID NO:28
SEQ ID NO:7/ SEQ ID NO:25
human isotype

Figure 7



chimeric SC104
SEQ ID NO:8/ SEQ ID NO:26
SEQ ID NO:8/ SEQ ID NO:10
SEQ ID NO:8/ SEQ ID NO:27
SEQ ID NO:8/ SEQ ID NO:29
human isotype
MFI
10000
1000
100
10
1
0.1
1
antibody concentration (µg/ml)

Figure 8



10000
1000
100
10
1
MFI
0.1
1
10
antibody concentration (µg/ml)
chimeric SC104
SEQ ID NO:4/ SEQ ID NO:30
SEQ ID NO:4/ SEQ ID NO:31
SEQ ID NO:4/ SEQ ID NO:32
human isotype

Figure 9



C170
MFI
10000
1000
100
10
1
0.01
0.1
1
antibody concentration (μg/ml)
chimeric SC104
SEQ ID NO:8/ SEQ ID NO:26
SEQ ID NO:8/ SEQ ID NO:38
SEQ ID NO:7/ SEQ ID NO:25
SEQ ID NO:7/ SEQ ID NO:50
human isotype
Colo205
MFI
10000
1000
100
10
1
0.01
0.1
1
antibody concentration(μg/ml)
HCT116
MFI
10000
1000
100
10
1
0.1
1
10
antibody concentration (μg/ml)

Figure 10:



10000
1000
100
10
1
MFI
0.01
0.1
1
antibody concentration (mg/ml)
chimeric SC104
SEQ ID NO:7/ SEQ ID NO:50
SEQ ID NO:7/ SEQ ID NO:62
SEQ ID NO:7/ SEQ ID NO:55
human isotype

Figure 11



10000
1000
100
10
1
MFI
0.01
0.1
1
antibody concentration (µg/ml)
chimeric SC104
SEQ ID NO:7/ SEQ ID NO:50
SEQ ID NO:7/ SEQ ID NO:75
SEQ ID NO:7/ SEQ ID NO:90
human isotype

Figure 12



% dead cells
60
40
20
0
1
10
100
antibody concentration (µg/ml)
chimeric SC104
SEQ ID NO:7/ SEQ ID NO:50
SEQ ID NO:7/ SEQ ID NO:25
SEQ ID NO:8/ SEQ ID NO:38
SEQ ID NO:8/ SEQ ID NO:26
human isotype

Figure 13



120
100
80
60
40
20
0
cytotoxicity (%)
0.001
0.01
0.1
1
antibody concentration (µg/ml)
chimeric SC104
SEQ ID NO:7/
SEQ ID NO:50
SEQ ID NO:7/
SEQ ID NO:25
SEQ ID NO:8/
SEQ ID NO:38
SEQ ID NO:8/
SEQ ID NO:26
human isotype

Figure 14



cytoxicity(%)
90
70
50
30
10
-10
0.01
0.1
1
10
antibody concentration (µg/ml)
chimeric SC104
SEQ ID NO:7/ SEQ ID NO:50
SEQ ID NO:7/ SEQ ID NO:25
SEQ ID NO:8/ SEQ ID NO:38
SEQ ID NO:8/ SEQ ID NO:26
human isotype

Figure 15



60
40
20
0
cytotoxicity (%)
0.01
0.1
1
10
antibody concentration (µg/ml)
Kifunensin-treated
Untreated

Figure 16



80
60
40
20
0
cytotoxicity (%)
0.0001
0.001
0.01
0.1
1
10
antibody concentration (µg/ml)
Potelligent-treated
untreated
human isotype

Figure 17




600
400
200
0
tumour volume (mm3)
0
5
10
15
20
25
day
vehicle control
antibody
p<0.005
0.6
0.4
0.2
0.0
tumour weight (g)
vehicle control
antibody

Figure 18


1200
1000
800
600
400
200
0
tumour volume (mm3)
0
10
20
30
40
day
* * * *
vehicle control
antibody